EIF2AK3 and cancer: These initial studies demonstrated that the pharmacological inhibition of PERK had an impact on tumor development in vivo not only by abolishing cancer cell protection against proteotoxic stress but also in certain instances by additional mechanisms, such as the inhibition of angiogenesis or the reactivation of the antitumor immune response.